Anagrelide is used to treat a certain blood disorder (thrombocythemia), which is caused by your bone marrow making too many platelets. Platelets are a blood cell that the body uses to form blood clots. Too many platelets can cause problems with your circulation, including unwanted blood clots and bleeding problems. This drug reduces the number of platelets in the bloodstream by blocking their production.
You should not use Bevyxxa if you are allergic to betrixaban, or if you have active or uncontrolled bleeding.
Bevyxxa may cause you to bleed more easily, especially if you have kidney disease or you use other medicines such as:
Bevyxxa can cause a very serious blood clot around your spinal cord if you undergo a spinal tap or receive spinal anesthesia (epidural). This type of blood clot could cause long-term paralysis, and may be more likely to occur if:
To make sure Bevyxxa is safe for you, tell your doctor if you have ever had:
It is not known whether this medicine will harm an unborn baby. However, taking this medicine during pregnancy may increase the risk of bleeding while you are pregnant or during your delivery. Tell your doctor if you are pregnant or plan to become pregnant.
Along with its needed effects, betrixaban (the active ingredient contained in Bevyxxa) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor immediately if any of the following side effects occur while taking betrixaban:
Some side effects of betrixaban may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.
Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:
Incidence not known
The recommended dose of BEVYXXA is an initial single dose of 160 mg, followed by 80 mg once daily. Daily oral doses should be given at the same time of day with food.
The recommended duration of treatment is 35 to 42 days.
For patients with severe renal impairment (CrCl ≥ 15 to < 30 mL/min computed by Cockcroft-Gault using actual body weight) the recommended dose of BEVYXXA is an initial single dose of 80 mg followed by 40 mg once daily [see WARNINGS AND PRECAUTIONS, Use In Specific Populations, CLINICAL PHARMACOLOGY]. The recommended duration of treatment is 35 to 42 days.
For patients receiving or starting concomitant P-gp inhibitors the recommended dose of BEVYXXA is an initial single dose of 80 mg followed by 40 mg once daily [see WARNINGS AND PRECAUTIONS, DRUG INTERACTIONS, CLINICAL PHARMACOLOGY]. The recommended duration of treatment is 35 to 42 days.
If a dose of BEVYXXA is not taken at the scheduled time, the dose should be taken as soon as possible on the same day. The BEVYXXA dose should not be doubled to make up for a missed dose.
What is the Generic Name for the trade name drug BEVYXXA® ?
Betrixaban is Generic Name for the trade name drug BEVYXXA®
What is the Manufacturer Name of BEVYXXA®?
BEVYXXA® is manufactured by Portola Pharmaceuticals.
Is BEVYXXA® approved by FDA?
Yes, BEVYXXA® is approved by FDA. Date of approval: 2017
What is the dosage and form of BEVYXXA® is available?
BEVYXXA® is available as capsules of 40mg and 80mg.
What is the Highlights of prescribing information of BEVYXXA®?
Mozocare is a medical access platform for hospitals and clinics to assist patients to access the best medical care at affordable prices. It offers medical information, medical treatment, pharmaceuticals, medical equipment, laboratory consumables, and other allied services.